Compare Amphastar Pharmaceuticals Inc (AMPH) vs Badger Meter Inc (BMI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Badger Meter (BMI) trades at $144.18, down 0.54% today, with a bullish technical outlook supported by moving averages and strong ADX readings. The company maintains solid profitability with 14.56% net margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create near-term uncertainty. Revenue declined to $897M in 2026 from $917M in 2025, while cash flow improved to positive $74M.

BMI presents a mixed investment case with strong fundamentals offset by legal risks. The stock trades near analyst consensus target of $144.80, offering limited upside. While operational metrics remain healthy, the pending class action and recent earnings volatility warrant caution. Institutional sentiment leans neutral with 55.55% hold ratings, suggesting investors await legal resolution and earnings stabilization.